Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04803539 | A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC(Artemis) | recruiting | Phase 2 / Phase 3 | 260 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05698186 | Thero2-01S22 in HER2-positive Breast Cancer | not yet recruiting | Phase 3 | 320 | Institut de cancérologie Strasbourg EuropeOTHER | 0 | Jan 26, 2023 |
| clinicaltrials |
| NCT03150576 | Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer(PARTNER) | recruiting | Phase 2 / Phase 3 | 780 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT01057069 | Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer(neo-TN) | active not recruiting | Phase 2 / Phase 3 | 310 | The Netherlands Cancer InstituteOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT01646034 | High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer(Oligo) | active not recruiting | Phase 3 | 74 | The Netherlands Cancer InstituteOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04263298 | Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer | recruiting | Phase 3 | 210 | Herui YaoOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT03829553 | Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment(HARVEST) | recruiting | Phase 3 | 801 | Ruijin HospitalOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05388500 | Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)(PHARE-C) | not yet recruiting | Phase 3 | 800 | Institut de cancérologie Strasbourg EuropeOTHER | 0 | May 27, 2022 | clinicaltrials |
| NCT04079049 | BreCLIM-2 - A RCT Investigating Local Treatment for Breast Cancer Liver Metastases(BreCLIM-2) | recruiting | Phase 3 | 200 | Umeå UniversityOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT05253170 | Hypo Versus Conventional Fractionation in Reconstructed-Breast Cancer Mastectomy Patients | not yet recruiting | Phase 3 | 622 | Seoul National University Bundang HospitalOTHER | 0 | Mar 11, 2022 | clinicaltrials |
| NCT02535221 | Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer | recruiting | Phase 3 | 234 | Peking UniversityOTHER | 1 | Nov 29, 2021 | clinicaltrials |
| NCT05059379 | Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer(SUCLANODE) | recruiting | Phase 3 | 1,650 | Fudan UniversityOTHER | 1 | Oct 25, 2021 | clinicaltrials |
| NCT04973319 | Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy | not yet recruiting | Phase 3 | 450 | Shengjing HospitalOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT04137653 | Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT | recruiting | Phase 3 | 1,498 | Shengjing HospitalOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT04736589 | Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway | not yet recruiting | Phase 3 | 270 | Peking Union Medical CollegeOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04646759 | Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer | recruiting | Phase 3 | 516 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT02568839 | Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer(PREDIX HER2) | active not recruiting | Phase 2 / Phase 3 | 202 | Thomas HatschekOTHER | 1 | Aug 13, 2020 | clinicaltrials |
| NCT04301739 | to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) | not yet recruiting | Phase 3 | 522 | Shanghai Henlius BiotechINDUSTRY | 0 | Mar 12, 2020 | clinicaltrials |
| NCT02338310 | Trial of Perioperative Endocrine Therapy - Individualising Care(POETIC) | active not recruiting | Phase 3 | 4,486 | Institute of Cancer Research, United KingdomOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT03561740 | A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients(SMART) | recruiting | Phase 3 | 794 | Sun Yat-sen UniversityOTHER | 1 | Jul 26, 2018 | clinicaltrials |
| NCT01185132 | Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy(2009-APBI) | recruiting | Phase 3 | 660 | Rocky Mountain Cancer CentersOTHER | 1 | Jun 26, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Feb 21, 2023source: clinicaltrials